Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 29, 2018	Jul. 27, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Central Index Key	0001114483
Document Type	10-Q
Document Period End Date	Jun. 29, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-28
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,165,953

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Jun. 29, 2018	Dec. 29, 2017
Current assets:
Cash and cash equivalents	$ 18,856	$ 37,341
Accounts receivable, net of allowance for doubtful accounts of $0.5 million, respectively	206,890	194,845
Inventories	194,977	176,738
Refundable income taxes	101	37
Prepaid expenses and other current assets	13,903	16,202
Current assets of discontinued operations held for sale	439,752	106,746
Total current assets	874,479	531,909
Property, plant and equipment, net	230,217	235,180
Goodwill	835,558	839,870
Other intangible assets, net	836,512	862,873
Deferred income taxes	3,573	3,451
Other assets	31,078	30,428
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0	344,634
Total assets	2,811,417	2,848,345
Current liabilities:
Current portion of long-term debt	35,156	30,469
Accounts payable	74,852	64,551
Income taxes payable	2,790	5,904
Accrued expenses	61,342	60,376
Current liabilities	56,243	47,703
Total current liabilities	230,383	209,003
Long-term debt	1,503,534	1,578,696
Deferred income taxes	149,442	140,964
Other long-term liabilities	10,324	11,335
Deferred taxes and other long-term liabilities	0	14,966
Total liabilities	1,893,683	1,954,964
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,218,208 and 31,977,953 shares issued, respectively; 32,096,437 and 31,871,427 shares outstanding, respectively	32	32
Additional paid-in capital	678,156	669,756
Treasury stock, at cost, 121,771 and 106,526 shares, respectively	(5,720)	(4,654)
Retained earnings	204,208	176,068
Accumulated other comprehensive income	41,058	52,179
Total stockholders’ equity	917,734	893,381
Total liabilities and stockholders’ equity	$ 2,811,417	$ 2,848,345

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Current assets:
Allowance for doubtful accounts	$ 0.5	$ 0.5
Stockholders’ equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,218,208	31,977,953
Common stock, shares outstanding	32,096,437	31,871,427
Treasury stock, shares	127,116	106,526

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Income Statement [Abstract]
Sales	$ 314,464	$ 280,916	$ 606,890	$ 547,652
Cost of sales	215,699	191,741	424,593	376,449
Gross profit	98,765	89,175	182,297	171,203
Operating expenses:
Selling, general and administrative expenses	36,780	35,146	73,209	69,940
Research, development and engineering costs	12,935	11,240	26,211	22,877
Other operating expenses	4,692	6,727	8,476	18,421
Total operating expenses	54,407	53,113	107,896	111,238
Operating income	44,358	36,062	74,401	59,965
Interest expense	15,234	15,058	30,829	33,425
(Gain) loss on cost and equity method investments, net	(284)	4,427	(5,254)	4,825
Other (income) loss, net	(2,387)	6,763	(1,427)	8,164
Income from continuing operations before taxes	31,795	9,814	50,253	13,551
Provision for income taxes	8,739	255	14,113	1,044
Income from continuing operations	23,056	9,559	36,140	12,507
Discontinued operations:
Loss from operations of discontinued operations	(1,374)	(5,698)	(7,623)	(13,630)
Provision for income taxes	1,660	871	377	226
Loss from discontinued operations	(3,034)	(6,569)	(8,000)	(13,856)
Net income (loss)	$ 20,022	$ 2,990	$ 28,140	$ (1,349)
Basic earnings (loss) per share:
Income from continuing operations (in dollars per share)	$ 0.72	$ 0.31	$ 1.13	$ 0.40
Loss from discontinued operations (in dollars per share)	(0.09)	(0.21)	(0.25)	(0.44)
Basic (in dollars per share)	0.62	0.10	0.88	(0.04)
Diluted earnings (loss) per share:
Income from continuing operations (in dollars per share)	0.70	0.30	1.11	0.39
Loss from discontinued operations (in dollars per share)	(0.09)	(0.21)	(0.25)	(0.44)
Diluted (in dollars per share)	$ 0.61	$ 0.09	$ 0.86	$ (0.04)
Weighted average shares outstanding:
Basic (in shares)	32,038	31,302	31,970	31,159
Diluted (in shares)	32,720	31,982	32,572	31,833

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 20,022	$ 2,990	$ 28,140	$ (1,349)
Other comprehensive income (loss):
Foreign currency translation gain	(25,885)	34,599	(12,444)	41,135
Net change in cash flow hedges, net of tax	(2,086)	318	1,323	2,068
Other comprehensive income	(27,971)	34,917	(11,121)	43,203
Comprehensive income	$ (7,949)	$ 37,907	$ 17,019	$ 41,854

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income (loss)	$ 28,140	$ (1,349)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	48,591	49,465
Debt related amortization included in interest expense	5,083	6,241
Stock-based compensation	6,107	7,950
Non-cash (gain) loss on cost and equity method investments	(763)	4,825
Other non-cash (gains) losses	(2,307)	6,542
Deferred income taxes	8,894	(2,447)
Changes in operating assets and liabilities:
Accounts receivable	(11,306)	(6,313)
Inventories	(20,948)	(9,451)
Prepaid expenses and other current assets	3,306	2,515
Accounts payable	8,898	15,373
Accrued expenses	(3,929)	215
Income taxes	(2,547)	3,599
Net cash provided by operating activities	67,219	77,165
Cash flows from investing activities:
Acquisition of property, plant and equipment	(19,224)	(22,438)
Purchase of cost and equity method investments	(831)	(497)
Other investing activities	(960)	(672)
Net cash used in investing activities	(19,095)	(22,263)
Cash flows from financing activities:
Principal payments of long-term debt	(75,062)	(118,839)
Proceeds from issuance of long-term debt	0	50,000
Proceeds from the exercise of stock options	3,625	8,725
Payment of debt issuance costs	(688)	(1,789)
Withholding tax paid related to stock-based compensation	(2,206)	0
Other financing activities	(192)	0
Net cash used in financing activities	(74,523)	(61,903)
Effect of foreign currency exchange rates on cash and cash equivalents	2,363	1,418
Net decrease in cash and cash equivalents	(24,036)	(5,583)
Cash and cash equivalents, beginning of period	44,096	52,116
Cash and cash equivalents, end of period	20,060	46,533
Total cash and cash equivalents, end of period	44,096	52,116
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 3,002	$ 4,825

Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 6 months ended Jun. 29, 2018 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, shares at Dec. 29, 2017		31,978		107
Balance at Dec. 29, 2017	$ 893,381	$ 32	$ 669,756	$ (4,654)	$ 176,068	$ 52,179
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	28,140				28,140
Other comprehensive loss, net	(11,121)					(11,121)
Stock-based compensation	6,107		6,107
Net shares issued, shares		240		(15)
Net shares issued	1,227	$ 0	2,293	$ (1,066)
Balance, shares at Jun. 29, 2018		32,218		122
Balance at Jun. 29, 2018	$ 917,734	$ 32	$ 678,156	$ (5,720)	$ 204,208	$ 41,058

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 29, 2018
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, vascular and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. On May 3, 2018, the Company announced that it entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC), and on July 2, 2018, completed the sale for $600 million in cash, subject to certain post-closing adjustments. As a result, the Company classified the results of operations of the AS&O Product Line as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented and classified the related assets and liabilities associated with the discontinued operations as held for sale in the Condensed Consolidated Balance Sheets. The Condensed Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes, and accordingly cash flow amounts for discontinued operations are disclosed in Note 2 “Discontinued Operations.” The Condensed Consolidated Balance Sheet as of December 29, 2017 was derived from the Company’s audited financial statements and has been retrospectively adjusted to reflect discontinued operations. All results and information in the condensed consolidated financial statements is presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. Refer to Note 2 “Discontinued Operations” and Note 17 “Subsequent Events” for additional information. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter of 2018 and 2017 each contained 13 weeks and ended on June 29, and June 30, respectively. The Company’s 2018 and 2017 fiscal years will end or ended on December 28, 2018 and December 29, 2017, respectively.

Discontinued Operations

6 Months Ended

Jun. 29, 2018

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

On May 3, 2018, the Company announced that it entered into a definitive agreement to sell its AS&O Product Line to Viant, and on July 2, 2018, completed the sale for $600 million in cash, subject to certain post-closing adjustments. Refer to Note 17 “Subsequent Events” for additional information.

For disposal transactions, a component of an entity that is anticipated to be sold in the future is reported in discontinued operations after it meets the criteria for held-for-sale classification, and if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The Company evaluated the quantitative and qualitative factors related to the expected sale of the AS&O Product Line and concluded that it met the held-for-sale criteria and that all other conditions for discontinued operations presentation were met as of May 3, 2018. Property, plant and equipment are not depreciated, and intangibles assets are not amortized once classified as held-for-sale.

As a result, the operating results of the AS&O Product Line have been classified as discontinued operations in the Condensed Consolidated Statements of Operations and for all periods presented and the assets and liabilities of the AS&O Product Line have been classified as assets and liabilities of discontinued operations in the Condensed Consolidated Balance Sheets at June 29, 2018 and December 29, 2017. The discontinued operations of the AS&O Product Line are reported in the Medical segment.

The assets and liabilities of a discontinued operation held for sale, other than goodwill, are measured at the lower of carrying amount or fair value less cost to sell. The assets of the AS&O Product Line, other than goodwill based on relative fair value, are measured at carrying amount. The fair value of the AS&O Product Line assets was based primarily on the purchase price of $600 million. In accordance with the guidance set forth in ASC 350, the Company calculated the portion of goodwill included in the AS&O Product Line and, using a relative fair value approach, allocated goodwill to discontinued operations from the Medical segment.

As of June 29 2018, all assets and liabilities of the AS&O Product Line are presented as current in the Condensed Consolidated Balance Sheet as management believes the sale transaction is deemed probable and proceeds will be collected within one year. The carrying amounts of the AS&O Product Line assets and liabilities that were classified as assets and liabilities of discontinued operations held for sale were as follows (in thousands):



	June 29, 2018		December 29, 2017
Cash and cash equivalents	$	1,204	$	6,755
Accounts receivable, net of allowance for doubtful accounts of $0.2 million and $0.3 million, respectively	45,757		47,611
Inventories	52,953		50,796
Prepaid expenses and other current assets	3,325		1,584
Property, plant and equipment, net	131,007		—
Goodwill	149,733		—
Other intangible assets, net	55,773		—
Current assets of discontinued operations held for sale	439,752		106,746
Property, plant and equipment, net	—		135,195
Goodwill	—		150,368
Other intangible assets, net	—		57,520
Other noncurrent assets	—		1,551
Noncurrent assets of discontinued operations held for sale	—		344,634
Total assets	439,752		451,380
Accounts payable and other current liabilities	51,843		47,703
Deferred taxes	4,400		—
Current liabilities of discontinued operations held for sale	56,243		47,703
Deferred taxes and other long-term liabilities	—		14,966
Total liabilities	56,243		62,669
Net assets	$	383,509	$	388,711

(2.) DISCONTINUED OPERATIONS (Continued)

Loss from discontinued operations, net of taxes, were as follows (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Sales	$	88,701		$	81,803		$	178,020		$	160,480
Cost of sales	71,276			71,706			148,357			141,185
Gross profit	17,425			10,097			29,663			19,295
Selling, general and administrative expenses	4,096			4,578			8,905			9,283
Research, development and engineering costs	1,090			1,649			2,352			3,423
Other operating expenses	2,497			193			3,990			270
Interest expense	11,007			10,589			21,857			21,115
Other (income) loss, net	109			(1,214		)	182			(1,166		)
Loss from operations of discontinued operations	(1,374		)	(5,698		)	(7,623		)	(13,630		)
Provision for income taxes	1,660			871			377			226
Loss from discontinued operations	$	(3,034	)	$	(6,569	)	$	(8,000	)	$	(13,856	)

The Company allocates interest to discontinued operations if the interest is directly attributable to the discontinued operations or is interest on debt that is required to be repaid as a result of the disposal transaction. Interest expense included in discontinued operations reflects an estimate of interest expense related to the debt that will be required to be repaid with the proceeds from the sale of the AS&O Product Line. Refer to Note 17 “Subsequent Events” for additional information.

Cash flow information from discontinued operations was as follows (in thousands):



	Six Months Ended
	June 29, 2018			June 30, 2017
Cash used in operating activities	$	(5,465	)	$	(1,692	)
Cash used in investing activities	(3,596		)	(9,141		)

Depreciation and amortization	$	7,450		$	10,507
Capital expenditures	3,610			9,214

Inventories

6 Months Ended

Jun. 29, 2018

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are comprised of the following (in thousands):



	June 29, 2018		December 29, 2017
Raw materials	$	85,767	$	85,050
Work-in-process	76,761		63,620
Finished goods	32,449		28,068
Total	$	194,977	$	176,738

Refer to Note 2 “Discontinued Operations” for inventories included in discontinued operations, which are not included above.

Goodwill and Other Intangible Assets, Net

6 Months Ended

Jun. 29, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

The changes in the carrying amount of goodwill by reportable segment for the quarter ended June 29, 2018 were as follows (in thousands):



	Medical			Non- Medical		Total
December 29, 2017	$	822,870		$	17,000	$	839,870
Foreign currency translation	(4,312		)	—		(4,312		)
June 29, 2018	$	818,558		$	17,000	$	835,558

Intangible Assets

Intangible assets at June 29, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
June 29, 2018
Definite-lived:
Purchased technology and patents	$	242,561	$	(118,399	)	$	124,162
Customer lists	713,930		(91,906		)	622,024
Other	4,660		(4,622		)	38
Total	$	961,151	$	(214,927	)	$	746,224
Indefinite-lived:
Trademarks and tradenames						$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	243,679	$	(111,185	)	$	132,494
Customer lists	718,649		(78,621		)	640,028
Other	4,660		(4,597		)	63
Total	$	966,988	$	(194,403	)	$	772,585
Indefinite-lived:
Trademarks and tradenames						$	90,288

Aggregate intangible asset amortization expense is comprised of the following (in thousands):



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Cost of sales	$	3,673	$	3,761	$	7,389	$	7,496
Selling, general and administrative expenses	6,808		6,250		13,706		12,462
Research, development and engineering costs	38		136		77		272
Discontinued operations	350		899		1,410		1,794
Total intangible asset amortization expense	$	10,869	$	11,046	$	22,582	$	22,024

Estimated future intangible asset amortization expense based on the carrying value as of June 29, 2018 is as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Amortization Expense	$	19,842	$	40,556	$	40,870	$	40,013	$	38,871	$	566,072

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt

6 Months Ended

Jun. 29, 2018

Debt Disclosure [Abstract]

DEBT

Long-term debt is comprised of the following (in thousands):



	June 29, 2018			December 29, 2017
Senior secured term loan A	$	321,094		$	335,157
Senior secured term loan B	812,286			873,286
9.125% senior notes due 2023	360,000			360,000
Revolving line of credit	74,000			74,000
Unamortized discount on term loan B and debt issuance costs	(28,690		)	(33,278		)
Total debt	1,538,690			1,609,165
Current portion of long-term debt	(35,156		)	(30,469		)
Total long-term debt	$	1,503,534		$	1,578,696

Senior Secured Credit Facilities

The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB facility was issued at a 1% discount.

On June 8, 2018, the Company amended the Senior Secured Credit Facilities to permit the sale of the AS&O Product Line, provided that the net cash proceeds from the sale be applied first, to redeem all of the Company’s outstanding 9.125% Senior Notes due 2023, second to repay the outstanding balance of the Company’s Revolving Credit Facility, and third, to the extent of any remaining net cash proceeds, to prepay outstanding loans under the TLB Facility. The amendment also amends the definition of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to permit adjustments consisting of certain non-recurring actual expenses incurred in connection with the sale of the AS&O Product Line.

The Company completed the sale of the AS&O Product Line on July 2, 2018 and subsequently utilized the net cash proceeds to repay the debt in accordance with the amended terms of the Senior Secured Credit Facilities. Refer to Note 17 “Subsequent Events” for additional information.

Revolving Credit Facility

The Revolving Credit Facility matures on October 27, 2020. The Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25%, based on the Company’s Total Net Leverage Ratio.

As of June 29, 2018, the Company had $74 million million of outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $116.8 million after giving effect to $9.2 million of outstanding standby letters of credit. As of June 29, 2018, the weighted average interest rate on all outstanding borrowings under the Revolving Credit Facility was 5.34%.

Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00. The outstanding amount of the Revolving Credit Facility approximated its fair value as of June 29, 2018 based upon the debt being variable rate and short-term in nature.

(5.) DEBT (Continued)

Term Loan Facilities

The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022, respectively. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 2.25% or (ii) the applicable LIBOR rate plus 3.25%, with LIBOR subject to a 1.00% floor. As of June 29, 2018, the interest rates on the TLA Facility and TLB Facility were 5.36% and 5.30%, respectively. Additionally, if the Company receives both (a) a public corporate family credit rating from Moody’s Investors Services, Inc. of “B2” (stable outlook) or higher and (b) a public corporate credit rating from Standard & Poor’s Financial Services LLC of “B” (stable outlook) or higher, the interest rate margins for the TLB Facility will step down by an additional 25 basis points. Refer to Note 17 “Subsequent Events” for additional information.

Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00.

As of June 29, 2018, the estimated fair value of the TLB Facility was approximately $815 million, based on quoted market prices for the debt, recent sales prices for the debt and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The par amount of the TLA Facility approximated its fair value as of June 29, 2018 based upon the debt being variable rate in nature.

Covenants

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 6.0:1.00, subject to periodic step downs beginning in the third quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 2.75:1.00 subject to a step up beginning in the first quarter of 2019. As of June 29, 2018, the Company was in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants.

The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of June 29, 2018, the Company was in compliance with all negative covenants under the Senior Secured Credit Facilities.

The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable.

9.125% Senior Notes due 2023

On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). All of the Senior Notes are outstanding as of June 29, 2018.

On June 8, 2018, the Company gave notice of a conditional full redemption for all of the Senior Notes. The redemption price for the Senior Notes is 100% of the principal amount of the Senior Notes plus the applicable premium (as set forth in the indenture governing the Senior Notes) and accrued and unpaid interest through the redemption date. The redemption was conditioned on the closing of the sale of the AS&O Product Line. On July 10, 2018, the Company completed the redemption in full of the Senior Notes. Refer to Note 17 “Subsequent Events” for additional information.

As of June 29, 2018, the estimated fair value of the Senior Notes was approximately $392 million, based on quoted market prices of these Senior Notes, recent sales prices for the Senior Notes and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy.

The indenture for the Senior Notes contain certain restrictive covenants and provides for customary events of default, subject in certain cases to customary cure periods, as a result of which the Senior Notes and any unpaid interest would become due and payable. As of June 29, 2018, the Company was in compliance with all restrictive covenants under the indenture governing the Senior Notes.

(5.) DEBT (Continued)

Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2018 and the next four years and thereafter, excluding any discounts or premiums, as of June 29, 2018 are as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Future minimum principal payments	$	16,406	$	37,500	$	111,500	$	229,688	$	812,286	$	360,000

Debt Issuance Costs and Discounts

The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands):



December 29, 2017	$	2,808
Amortization during the period	(495		)
June 29, 2018	$	2,313

The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):



	Debt Issuance Costs			Unamortized Discount on TLB Facility			Total
December 29, 2017	$	26,889		$	6,389		$	33,278
Write-off of debt issuance costs and unamortized discount⁽¹⁾	(1,039		)	(435		)	(1,474		)
Amortization during the period	(2,544		)	(570		)	(3,114		)
June 29, 2018	$	23,306		$	5,384		$	28,690

⁽¹⁾

The Company prepaid portions of its TLB Facility during 2018 and 2017. The Company recognized losses from extinguishment of debt during the three and six months ended June 29, 2018 of $0.4 million and $1.5 million, respectively. The Company recognized losses from extinguishment of debt during the three and six months ended June 30, 2017 of $0.9 million and $2.5 million, respectively. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations.

Interest Rate Swap

During 2016, the Company entered into a three-year $200 million interest rate swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge.

Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of June 29, 2018 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	Pay Fixed Rate		Receive Current Floating Rate		Fair Value		Balance Sheet Location
$	200,000	Jun-17	Jun-20	1.1325	%	2.1029	%	$	5,756	Other Long-Term Assets

The estimated fair value of the interest rate swap agreement represents the amount the Company would receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swap during the quarters ended June 29, 2018 and June 30, 2017 was considered ineffective. The amounts recorded to Interest Expense during the six months ended June 29, 2018 and June 30, 2017 related to the Company’s interest rate swap were reductions of $0.6 million and $0.3 million, respectively. The estimated Accumulated Other Comprehensive Income related to the Company’s interest rate swaps that is expected to be reclassified into earnings within the next twelve months is a $2.5 million gain.

Benefit Plans

6 Months Ended

Jun. 29, 2018

Defined Benefit Plan [Abstract]

BENEFIT PLANS

The Company is required to provide its employees located in Switzerland, Mexico, France, and Germany certain statutorily mandated defined benefits. Net defined benefit cost attributable to employees of the AS&O Product Line located in France and Germany are reported within discontinued operations.

The following tables set forth the components of the Company’s net periodic expense relating to retirement benefit plans (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Service cost	$	122		$	115		$	249		$	225
Interest cost	45			40			91			78
Amortization of net loss	16			19			32			36
Expected return on plan assets	(5		)	(6		)	(9		)	(10		)
Net defined benefit cost	178			168			363			329
Less: Discontinued operations	109			101			223			198
Net defined benefit cost - continuing operations	$	69		$	67		$	140		$	131

Stock-Based Compensation

6 Months Ended

Jun. 29, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, shares of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.

The components and classification of stock-based compensation expense were as follows (in thousands):



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Stock options	$	214	$	283	$	545	$	993
RSAs and RSUs (time-based)	1,338		1,155		3,416		3,359
Performance-based RSUs (“PSUs”)	1,333		1,843		2,146		3,598
Total stock-based compensation expense	2,885		3,281		6,107		7,950
Less: Discontinued operations	685		349		924		582
Stock-based compensation expense - continuing operations	$	2,200	$	2,932	$	5,183	$	7,368

Cost of sales	$	200	$	259	$	376	$	337
Selling, general and administrative expenses	1,968		2,493		4,747		4,493
Research, development and engineering costs	31		150		55		245
Other operating expenses	1		30		5		2,293
Discontinued operations	685		349		924		582
Total stock-based compensation expense	$	2,885	$	3,281	$	6,107	$	7,950

(7.) STOCK-BASED COMPENSATION (Continued)

During the first quarter of 2017, the Company recorded $2.2 million of accelerated stock-based compensation expense in connection with the transition of its former Chief Executive Officer per the terms of his contract, which was classified as Other Operating Expenses.

The weighted average fair value and assumptions used to value options granted are as follows:



	Six Months Ended
	June 29, 2018			June 30, 2017
Weighted average fair value	$	14.89		$	10.58
Risk-free interest rate	2.21		%	1.69		%
Expected volatility	39		%	37		%
Expected life (in years)	4.0			4.1
Expected dividend yield	—		%	—		%

The following table summarizes the Company’s stock option activity:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Millions)
Outstanding at December 29, 2017	931,353		$	30.89
Granted	28,447		45.13
Exercised	(108,305	)	33.47
Forfeited or expired	(17,542	)	38.77
Outstanding at June 29, 2018	833,953		$	30.87	5.4	$	28.2
Exercisable at June 29, 2018	701,729		$	29.88	4.8	$	24.4

During the six months ended June 29, 2018, the Company awarded grants of 0.3 million RSUs to certain members of management, of which 0.2 million are PSUs and the remainder are time-based RSUs that vest over three years. Of the PSUs, 0.1 million of the shares subject to each grant will be earned based upon achievement of specific Company performance metrics over a three-year performance period ending January 1, 2021, and 0.1 million of the shares subject to each grant will be earned based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over a three-year performance period ending January 1, 2021. The number of PSUs earned based on the achievement of the Company performance metrics and TSR performance requirements, if any, will vest based on the recipient’s continuous service to the Company over a period of generally one to three years from the grant date. The time-based RSUs generally vest ratably over a three-year period.

The grant-date fair value of the TSR portion of the PSUs granted during the six months ended June 29, 2018 was determined using the Monte Carlo simulation model on the date of grant, assuming the following (i) expected term of 2.92 years, (ii) risk free interest rate of 2.28%, (iii) expected dividend yield of 0.0% and (iv) expected stock price volatility over the expected term of the TSR award of 40%. The grant-date fair value of all other restricted stock awards is equal to the closing market price of Integer common stock on the date of grant.

(7.) STOCK-BASED COMPENSATION (Continued)

The following table summarizes RSA and RSU activity:



	Time-Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	163,431		$	35.96
Granted	147,878		49.30
Vested	(11,999	)	49.78
Forfeited	(4,453	)	43.62
Nonvested at June 29, 2018	294,857		$	41.97

The following table summarizes PSU activity:



	Performance- Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	469,889		$	32.37
Granted	159,669		45.37
Vested	(127,191	)	34.29
Forfeited	(147,555	)	34.31
Nonvested at June 29, 2018	354,812		$	36.72

Other Operating Expenses, Net

6 Months Ended

Jun. 29, 2018

Other Income and Expenses [Abstract]

OTHER OPERATING EXPENSES, NET

OTHER OPERATING EXPENSES

Other Operating Expenses is comprised of the following (in thousands):



	Three Months Ended					Six Months Ended
	June 29, 2018			June 30, 2017		June 29, 2018		June 30, 2017
Strategic reorganization and alignment	$	3,727		$	—	$	5,781	$	—
Manufacturing alignment to support growth	1,103			—		1,616		—
Consolidation and optimization initiatives	(14		)	2,729		561		5,076
Acquisition and integration expenses	—			2,970		—		7,790
Asset dispositions, severance and other	(124		)	1,028		518		5,555
Other operating expenses - continuing operations	4,692			6,727		8,476		18,421
Discontinued operations	2,497			193		3,990		270
Total other operating expenses	$	7,189		$	6,920	$	12,466	$	18,691

Strategic Reorganization and Alignment

During the fourth quarter of 2017, the Company began to take steps to better align its resources in order to enhance the profitability of its portfolio of products. This includes improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan, including projects currently classified as discontinued operations, of between approximately $28 million to $30 million, of which an estimated $16 million to $20 million are expected to result in cash outlays. During the six months ended June 29, 2018, the Company incurred charges relating to this initiative which primarily included severance and personnel related costs for terminated employees and fees for professional services. These expenses were primarily recorded within the Medical segment. As of June 29, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $15.5 million. These actions are expected to be substantially completed by the end of the third quarter of 2018.

(8.) OTHER OPERATING EXPENSES (Continued)

Manufacturing Alignment to Support Growth

In 2017, the Company initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $9 million to $11 million, the majority of which are expected to be cash expenditures, and capital expenditures of between approximately $4 million to $6 million. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of June 29, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $2.0 million. These actions are expected to be substantially completed by the end of 2019.

Consolidation and Optimization Initiatives

In 2014, the Company initiated plans to transfer certain manufacturing functions performed at its facility in Beaverton, OR to a new facility in Tijuana, Mexico. Additionally, during 2016, the Company announced it would be closing its facility in Clarence, NY after transferring the machined component product lines manufactured in that facility to other Integer locations in the U.S. Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical segment. The Company does not expect to incur any material additional costs associated with these activities are substantially complete.

The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):



	Severance and Retention			Other			Total
December 29, 2017	$	1,308		$	—		$	1,308
Restructuring charges	4,427			3,531			7,958
Cash payments	(4,514		)	(1,336		)	(5,850		)
June 29, 2018	$	1,221		$	2,195		$	3,416

Acquisition and Integration Expenses

The Company did not incur any additional costs associated with these activities during the six months ended June 29, 2018. During the three and six months ended June 30, 2017, the Company incurred $3.0 million and $7.8 million in acquisition and integration costs related to the acquisition of Lake Region Medical, consisting primarily of integration costs. Integration costs primarily include professional, consulting, severance, retention, relocation, and travel costs. The $0.4 million of acquisition and integration costs accrued as of December 29, 2017 were paid during the first quarter of 2018. These projects were completed as of December 29, 2017.

Asset Dispositions, Severance and Other

During the first six months of 2018 and 2017, the Company recorded losses in connection with various asset disposals and/or write-downs. The 2017 amount also includes approximately $5.3 million in expense related to the Company’s leadership transitions, which were recorded within the corporate unallocated segment.

Income Taxes	6 Months Ended
Income Taxes	Jun. 29, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. Under GAAP, the effect of a change in tax laws or rates to be recognized in income from continuing operations for the period that includes the enactment date. As such, the Company recognized an estimate of the impact of the Tax Reform Act in the year ended December 29, 2017. The Company had an estimated $147.5 million of undistributed foreign earnings and profit subject to the deemed mandatory repatriation as of December 29, 2017 and recognized a provisional $14.7 million in 2017 for the one-time transition tax. The Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In addition, as a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its ending net deferred tax liabilities at December 29, 2017 and recognized a $56.5 million tax benefit in the Company’s Consolidated Statement of Operations and Comprehensive Income (Loss) for the year ended December 29, 2017. For further discussion of the impact of the Tax Reform Act for the year ended December 29, 2017, reference is made to Note 12 of the Company’s consolidated financial statements as of and for the year ended December 29, 2017 included in the Company’s 2017 Annual Report on Form 10-K for the year ended December 29, 2017. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. The Company recognized the tax impact of the revaluation of deferred tax assets and liabilities and the provisional tax impact related to deemed repatriated earnings and included these amounts in its consolidated financial statements for the year ended December 29, 2017. The ultimate impact may differ from the provisional amount, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Reform Act. This accounting is expected to be complete by the date that the Company’s 2017 U.S. corporate income tax return is filed in 2018. During the six month period ended June 29, 2018, there were no changes made to the provisional amount recorded in 2017. In addition to the reduction of the U.S. federal corporate tax rate and the one-time transition tax discussed above, the Tax Reform Act also established new tax laws that affect 2018, including, but not limited to: (i) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (ii) a new U.S. Income inclusion on certain earnings of foreign subsidiaries (Global Intangible Low-Taxed Income (“GILTI”)); (iii) the repeal of the domestic production activity deductions; (iv) limitations on the deductibility of certain executive compensation; (v) an elimination of the deduction for certain deemed “base erosion payments” made to foreign affiliates (Base Erosion and Anti-Abuse Tax (“BEAT”)); and (vi) a new provision that allows a domestic corporation an immediate deduction for a portion of its foreign derived intangible income (“FDII”). (9.) INCOME TAXES (Continued) The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. The Company expects that it will be subject to incremental U.S. tax on GILTI income beginning in 2018. Because of the complexity of the new GILTI tax rules and the ongoing regulatory interpretation of the GILTI provisions, the Company is continuing its evaluation of this provision of the Tax Reform Act and the application of ASC 740, Income Taxes. Under GAAP, the Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only the Company's current structure and estimated future results of global operations, but also its intent and ability to modify its structure. While the Company has included an estimate of GILTI in its estimated effective tax rate for 2018, it has not finalized its analysis and is not yet able to determine which method to elect. Adjustments related to the amount of GILTI Tax recorded in its condensed consolidated financial statements may be required based on the outcome of this election. The BEAT provisions in the Tax Reform Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company does not expect to be materially impacted by the BEAT or FDII provisions and has not included any impact of the provisions in its estimated effective tax rate for 2018, however, it is still in the process of analyzing the effect of these provisions of the Tax Reform Act. The Company’s worldwide effective tax rate for the second quarter of 2018 was 27.5% on $31.8 million of income from continuing operations before taxes compared to 2.6% on $9.8 million of income from continuing operations before taxes for the same period in 2017. The Company recognized a tax provision of $14.1 million on income from continuing operations before taxes of $50.3 million for the first six months of 2018 compared to $1.0 million on $13.6 million of income from continuing operations before taxes for the same period of 2017. The 2018 estimated annual effective tax rate includes the estimated impact of all Tax Reform Act provisions. The Company’s effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. The Company’s earnings outside the United States are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. The Company currently has net operating losses to offset forecasted U.S. taxable income and as such, is temporarily subject to the deduction limitation which correspondingly imposes an incremental impact on U.S. income tax. The foreign jurisdictions in which the Company operates and where its foreign earnings are primarily derived, include Switzerland, Mexico, Germany, Uruguay, Malaysia and Ireland. The Company’s effective tax rate for 2017 differs from the U.S. federal statutory tax rate of 35% due principally to the Company’s earnings outside the U.S. which are generally taxed at rates lower than the U.S. federal rate. In addition, the Company had positive income before taxes in its foreign jurisdictions but losses before taxes in U.S. jurisdictions. As of June 29, 2018, the balance of unrecognized tax benefits from continuing operations is approximately $6.5 million. It is reasonably possible that a reduction of up to $1.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $6.2 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments and Contingencies

6 Months Ended

Jun. 29, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future.

(10.) COMMITMENTS AND CONTINGENCIES (Continued)

In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. On January 26, 2016, a jury in the U.S. District Court for the District of Delaware returned a verdict finding that AVX infringed two Integer patents and awarded Integer $37.5 million in damages. Following a second trial in August 2017, a jury found that AVX infringed an additional Integer patent. On March 30, 2018, the U.S. District Court for the District of Delaware vacated the original damage award and ordered a retrial on damages, which is scheduled for January 2019. The Company has recorded no gains in connection with this litigation as no cash has been received.

Product Warranties

The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its condensed consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The change in product warranty liability was comprised of the following (in thousands):



December 29, 2017	$	2,820
Additions to warranty reserve	555
Warranty claims settled	(78		)
June 29, 2018	$	3,297

Foreign Currency Contracts

The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. Accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in Accumulated Other Comprehensive Income in the Condensed Consolidated Balance Sheets and are reclassified to earnings in the same periods during which the hedged transactions affect earnings. The estimated Accumulated Other Comprehensive Income related to the Company’s foreign currency contracts that is expected to be reclassified into earnings within the next twelve months is a $0.7 million gain.

The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Increase (decrease) in sales	$	(141	)	$	163		$	(2	)	$	139
Increase (decrease) in cost of sales	(159		)	(179		)	(595		)	883
Ineffective portion of change in fair value	—			—			—			—

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of June 29, 2018 is as follows (dollars in thousands):



Aggregate Notional Amount		Start Date	End Date	$/Foreign Currency		Fair Value			Balance Sheet Location
$	3,000	Jul 2018	Dec 2018	0.0500	Peso	$	(16	)	Accrued expenses
15,199		Jan 2018	Dec 2018	0.0507	Peso	(313		)	Accrued expenses
12,300		Jan 2018	Dec 2018	1.2059	Euro	(333		)	Accrued expenses

Earnings (Loss) Per Share (EPS)

6 Months Ended

Jun. 29, 2018

Earnings Per Share [Abstract]

EARNINGS (LOSS) PER SHARE (EPS)

EARNINGS (LOSS) PER SHARE (“EPS”)

The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Numerator for basic and diluted EPS:
Income from continuing operations	$	23,056		$	9,559		$	36,140		$	12,507
Loss from operations of discontinued operations	(3,034		)	$	(6,569	)	(8,000		)	(13,856		)
Net income (loss)	$	20,022		$	2,990		$	28,140		$	(1,349	)

Denominator for basic and diluted EPS:
Weighted average shares outstanding - Basic	32,038			31,302			31,970			31,159
Dilutive effect of assumed exercise of stock options, restricted stock and RSUs	682			680			602			674
Weighted average shares outstanding - Diluted	32,720			31,982			32,572			31,833

Basic earnings (loss) per share:
Income from continuing operations	$	0.72		$	0.31		$	1.13		$	0.40
Loss from discontinued operations	(0.09		)	(0.21		)	(0.25		)	(0.44		)
Basic earnings (loss) per share	0.62			0.10			0.88			(0.04		)

Diluted earnings (loss) per share:
Income from continuing operations	$	0.70		$	0.30		$	1.11		$	0.39
Loss from discontinued operations	(0.09		)	(0.21		)	(0.25		)	(0.44		)
Diluted earnings (loss) per share	0.61			0.09			0.86			(0.04		)

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):



	Three Months Ended		Six Months Ended
	June 29, 2018	June 30, 2017	June 29, 2018	June 30, 2017
Time-vested stock options, restricted stock and RSUs	—	556	50	1,599
Performance-vested restricted stock and PSUs	92	180	122	451

Accumulated Other Comprehensive Income (Loss)

6 Months Ended

Jun. 29, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated Other Comprehensive Income is comprised of the following (in thousands):



	Defined Benefit Plan Liability			Cash Flow Hedges			Foreign Currency Translation Adjustment			Total Pre-Tax Amount			Tax			Net-of-Tax Amount
March 30, 2018	$	(1,422	)	$	7,733		$	63,641		$	69,952		$	(923	)	$	69,029
Unrealized loss on cash flow hedges	—			(2,223		)	—			(2,223		)	467			(1,756		)
Realized gain on foreign currency hedges	—			(18		)	—			(18		)	3			(15		)
Realized gain on interest rate swap hedges	—			(398		)	—			(398		)	83			(315		)
Foreign currency translation loss	—			—			(25,885		)	(25,885		)	—			(25,885		)
June 29, 2018	$	(1,422	)	$	5,094		$	37,756		$	41,428		$	(370	)	$	41,058

December 29, 2017	$	(1,422	)	$	3,418		$	50,200		$	52,196		$	(17	)	$	52,179
Unrealized gain on cash flow hedges	—			2,901			—			2,901			(609		)	2,292
Realized gain on foreign currency hedges	—			(593		)	—			(593		)	124			(469		)
Realized gain on interest rate swap hedges	—			(632		)	—			(632		)	132			(500		)
Foreign currency translation loss	—			—			(12,444		)	(12,444		)	—			(12,444		)
June 29, 2018	$	(1,422	)	$	5,094		$	37,756		$	41,428		$	(370	)	$	41,058



March 31, 2017	$	(1,475	)	$	4,112		$	(9,124	)	$	(6,487	)	$	(1,227	)	$	(7,714	)
Unrealized gain on cash flow hedges	—			1,069			—			1,069			(374		)	695
Realized gain on foreign currency hedges	—			(342		)	—			(342		)	120			(222		)
Realized gain on interest rate swap hedges	—			(238		)	—			(238		)	83			(155		)
Foreign currency translation gain	—			—			34,599			34,599			—			34,599
June 30, 2017	$	(1,475	)	$	4,601		$	25,475		$	28,601		$	(1,398	)	$	27,203

December 30, 2016	$	(1,475	)	$	1,420		$	(15,660	)	$	(15,715	)	$	(285	)	$	(16,000	)
Unrealized gain on cash flow hedges	—			2,781			—			2,781			(973		)	1,808
Realized loss on foreign currency hedges	—			744			—			744			(260		)	484
Realized gain on interest rate swap hedges	—			(344		)	—			(344		)	120			(224		)
Foreign currency translation gain	—			—			41,135			41,135			—			41,135
June 30, 2017	$	(1,475	)	$	4,601		$	25,475		$	28,601		$	(1,398	)	$	27,203

The realized loss (gain) relating to the Company’s foreign currency hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales or Sales as the transactions they are hedging occur. The realized gain relating to the Company’s interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Interest Expense as interest on the corresponding debt being hedged is accrued.

Fair Value Measurements

6 Months Ended

Jun. 29, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company also holds cost method and equity method investments which are measured at fair value on a nonrecurring basis.

Foreign Currency Contracts

The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparties to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. Refer to Note 10 “Commitments and Contingencies” for further discussion regarding the fair value of the Company’s foreign currency contracts.

Interest Rate Swaps

The fair value of the Company’s interest rate swap contracts outstanding were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. Refer to Note 5 “Debt” for further discussion regarding the fair value of the Company’s interest rate swap.

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):



	Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
June 29, 2018
Assets: Interest rate swap (Note 5)	$	5,756	$	—	$	5,756	$	—
Liabilities: Foreign currency contracts (Note 10)	662		—		662		—

December 29, 2017
Assets: Interest rate swaps	$	4,279	$	—	$	4,279	$	—
Liabilities: Foreign currency contracts	861		—		861		—

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Refer to Note 5 “Debt” for further discussion regarding the fair value of the Company’s Senior Secured Credit Facilities and Senior Notes. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows:

Cost and Equity Method Investments

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments are not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. The aggregate recorded amount of cost and equity method investments at June 29, 2018 and December 29, 2017 was $22.4 million and $20.8 million, respectively.

(13.) FAIR VALUE MEASUREMENTS (Continued)

As of June 29, 2018 and December 29, 2017, the recorded amount of the Company’s equity method investment was $14.7 million and $13.8 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of June 29, 2018, the Company owned 6.6% of this fund. During the six months ended June 29, 2018 and June 30, 2017, the Company recognized net gains of $5.0 million and $0.2 million, respectively, on its equity method investment.

The Company’s recorded amount of cost method investments was $7.7 million at June 29, 2018 and December 29, 2017.

The Company did not recognize any impairment charges related to cost method investments during the six months ended June 29, 2018. The Company recognized impairment charges of $5.0 million related to its cost method investments during the six months June 30, 2017. The fair value of these investments is primarily determined by reference to recent sales data of similar shares to independent parties in an inactive market and categorized in Level 2 of the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segment Information

6 Months Ended

Jun. 29, 2018

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting. There were no sales between segments during the six months ended June 29, 2018 and June 30, 2017.

The following table presents sales from continuing operations by product line (in thousands).



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Segment sales from continuing operations by product line:
Medical
Cardio & Vascular	$	148,766	$	130,718	$	285,629	$	254,202
Cardiac & Neuromodulation	115,941		106,173		224,851		209,928
Advanced Surgical, Orthopedics & Portable Medical	34,751		28,282		68,692		56,433
Total Medical	299,458		265,173		579,172		520,563
Non-Medical	15,006		15,743		27,718		27,089
Total sales from continuing operations	$	314,464	$	280,916	$	606,890	$	547,652

The following table presents income from continuing operations for the Company’s reportable segments (in thousands).



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Segment income from continuing operations:
Medical	$	61,179		$	51,557		$	108,694		$	99,274
Non-Medical	4,393			4,940			7,591			6,502
Total segment income from continuing operations	65,572			56,497			116,285			105,776
Unallocated operating expenses	(21,214		)	(20,435		)	(41,884		)	(45,811		)
Operating income from continuing operations	44,358			36,062			74,401			59,965
Unallocated expenses, net	(12,563		)	(26,248		)	(24,148		)	(46,414		)
Income before taxes from continuing operations	$	31,795		$	9,814		$	50,253		$	13,551

Revenue From Contracts With Customers

6 Months Ended

Jun. 29, 2018

Revenue from Contract with Customer [Abstract]

REVENUE FROM CONTRACTS WITH CUSTOMERS

The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The Company has elected to adopt the practical expedient provided in ASC 340-40-25-4 and recognize the incremental costs of obtaining a contract, which are primarily sales commissions, as expense when incurred because the amortization period is less than one year.

Performance Obligations

The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and can include a discount for early payment.

The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Historically, warranty reserves have not been material.

Transaction Price

Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and updated quarterly. Any adjustments to these estimates are recognized under the cumulative catch-up method, such that impact of the adjustment is recognized in the period in which it is identified.

The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.

The Company has elected to adopt the practical expedient provided in ASC 606-10-50-14 and not disclose the aggregate amount of the transaction price allocated to unsatisfied performance obligations and an expectation of when those amounts are expected to be recognized as revenue because the majority of contracts have an original expected duration of one year or less.

Revenue Recognition

The Company recognizes revenue at the point in time when a performance obligation is satisfied and the customer has obtained control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the product. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Accordingly, the majority of the Company’s revenues are recognized at the point of shipment. In instances where title and risk of ownership do not transfer to the customer until the products have reached the customer’s location, revenue is recognized at that point in time. Revenue is recognized net of sales tax, value-added taxes and other taxes.

Contract Modifications

Contract modifications, which can include a change in either or both scope and price, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.


(15.)	REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)

Disaggregated Revenue

In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 14, “Segment Information.” Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors.

The following table presents revenues by customer.



	Three Months Ended				Six Months Ended
	June 29, 2018				June 29, 2018
Customer	Medical		Non-Medical		Medical		Non-Medical
Customer A	21	%	—	%	21	%	—	%
Customer B	20	%	—	%	20	%	—	%
Customer C	11	%	—	%	11	%	—	%
Customer D	—	%	35	%	—	%	28	%
All other customers	48	%	65	%	48	%	72	%

The following table presents revenues by ship to country.



	Three Months Ended		Six Months Ended
	June 29, 2018		June 29, 2018
Ship to Location	Medical	Non-Medical	Medical	Non-Medical
United States	55%	69%	56%	69%
Puerto Rico	13%	—%	13%	—%
Canada	—%	—%	—%	10%
All other Countries	32%	31%	31%	21%

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities were $3.2 million and $2.2 million as of June 29, 2018 and December 29, 2017, respectively, and are classified as Accrued Expenses on the Condensed Consolidated Balance Sheets. During the three and six months ended June 29, 2018, the Company recognized $0.9 million and $1.3 million, respectively, of revenue that was included in the contract liability balance as of December 29, 2017. The Company does not have any contract assets.

Impact of Recently Issued Accounting Standards

6 Months Ended

Jun. 29, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB"):



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.	The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users.	December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.	The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.
In August 2017, the FASB issued ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities.	The new guidance improves the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results.	December 29, 2018. Early adoption is permitted.	The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.
In March 2017, the FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.	The new guidance clarifies the presentation and classification of the components of net periodic benefit costs in the consolidated statement of operations.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, the beginning of its 2018 fiscal year, using the retrospective transition method, as part of the FASB's simplification initiative. See Adoption of ASU 2017-07 section below for additional information.
In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory.	The new guidance requires the income tax consequences of an intra-entity transfer of assets other than inventory to be recognized when the transfer occurs rather than deferring until an outside sale has occurred.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments.	The new guidance clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In February 2016, the FASB issued ASU 2016-02, Leases.	The new guidance supersedes the lease guidance under ASC Topic 840, Leases, resulting in the creation of FASB ASC Topic 842, Leases. The guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.	December 29, 2018. Early adoption is permitted.	The Company is currently evaluating its population of leases, and is continuing to assess all potential impacts of the standard, but currently believes the most significant impact relates to its accounting for real estate operating leases. The Company anticipates recognition of additional assets and corresponding liabilities related to leases upon adoption, but has not yet quantified these at this time. The Company plans to adopt the standard effective December 29, 2018.

(16.) IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.	The new guidance updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. Since that date, the FASB has issued additional ASUs clarifying certain aspects of ASU 2014-09.	The new guidance requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provides alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. (See Note 15, “Revenue from Contracts with Customers”).

Adoption of ASU 2017-07

On December 30, 2017, the Company retrospectively adopted the new accounting guidance on presentation of net periodic pension costs (ASU 2017-07). That guidance requires that the service cost component of net benefit costs be disaggregated and reported in the same line item or items in the Condensed Consolidated Statements of Operations and Comprehensive Income as other compensation costs arising from services rendered by the pertinent employees during the period. The other non-service components of net benefit costs are required to be presented separately from the service cost component.

Following the adoption of this guidance, the Company continues to record the service cost component of net benefit costs in Cost of Sales and Selling, General and Administrative expenses. The interest cost component of net benefit costs is now recorded in Interest Expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are now recorded in Other (Income) Loss, Net.

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 29, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENTS On July 2, 2018, the Company completed the sale of the AS&O Product Line to Viant, for cash consideration of $600 million

Basis of Presentation (Policies)	6 Months Ended
Basis of Presentation (Policies)	Jun. 29, 2018
Accounting Policies [Abstract]
Interim Basis of Accounting	For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter of 2018 and 2017 each contained 13 weeks and ended on June 29, and June 30, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Discontinued Operations (Tables)

6 Months Ended

Jun. 29, 2018

Discontinued Operations and Disposal Groups [Abstract]

Summary of discontinued operations

Cash flow information from discontinued operations was as follows (in thousands):



	Six Months Ended
	June 29, 2018			June 30, 2017
Cash used in operating activities	$	(5,465	)	$	(1,692	)
Cash used in investing activities	(3,596		)	(9,141		)

Depreciation and amortization	$	7,450		$	10,507
Capital expenditures	3,610			9,214

The carrying amounts of the AS&O Product Line assets and liabilities that were classified as assets and liabilities of discontinued operations held for sale were as follows (in thousands):



	June 29, 2018		December 29, 2017
Cash and cash equivalents	$	1,204	$	6,755
Accounts receivable, net of allowance for doubtful accounts of $0.2 million and $0.3 million, respectively	45,757		47,611
Inventories	52,953		50,796
Prepaid expenses and other current assets	3,325		1,584
Property, plant and equipment, net	131,007		—
Goodwill	149,733		—
Other intangible assets, net	55,773		—
Current assets of discontinued operations held for sale	439,752		106,746
Property, plant and equipment, net	—		135,195
Goodwill	—		150,368
Other intangible assets, net	—		57,520
Other noncurrent assets	—		1,551
Noncurrent assets of discontinued operations held for sale	—		344,634
Total assets	439,752		451,380
Accounts payable and other current liabilities	51,843		47,703
Deferred taxes	4,400		—
Current liabilities of discontinued operations held for sale	56,243		47,703
Deferred taxes and other long-term liabilities	—		14,966
Total liabilities	56,243		62,669
Net assets	$	383,509	$	388,711

(2.) DISCONTINUED OPERATIONS (Continued)

Loss from discontinued operations, net of taxes, were as follows (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Sales	$	88,701		$	81,803		$	178,020		$	160,480
Cost of sales	71,276			71,706			148,357			141,185
Gross profit	17,425			10,097			29,663			19,295
Selling, general and administrative expenses	4,096			4,578			8,905			9,283
Research, development and engineering costs	1,090			1,649			2,352			3,423
Other operating expenses	2,497			193			3,990			270
Interest expense	11,007			10,589			21,857			21,115
Other (income) loss, net	109			(1,214		)	182			(1,166		)
Loss from operations of discontinued operations	(1,374		)	(5,698		)	(7,623		)	(13,630		)
Provision for income taxes	1,660			871			377			226
Loss from discontinued operations	$	(3,034	)	$	(6,569	)	$	(8,000	)	$	(13,856	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Inventories (Tables)

6 Months Ended

Jun. 29, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

Inventories are comprised of the following (in thousands):



	June 29, 2018		December 29, 2017
Raw materials	$	85,767	$	85,050
Work-in-process	76,761		63,620
Finished goods	32,449		28,068
Total	$	194,977	$	176,738

Goodwill and Other Intangible Assets, Net (Tables)

6 Months Ended

Jun. 29, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill by reportable segment for the quarter ended June 29, 2018 were as follows (in thousands):



	Medical			Non- Medical		Total
December 29, 2017	$	822,870		$	17,000	$	839,870
Foreign currency translation	(4,312		)	—		(4,312		)
June 29, 2018	$	818,558		$	17,000	$	835,558

Schedule of Finite-Lived Intangible Assets, Major Class

Intangible assets at June 29, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
June 29, 2018
Definite-lived:
Purchased technology and patents	$	242,561	$	(118,399	)	$	124,162
Customer lists	713,930		(91,906		)	622,024
Other	4,660		(4,622		)	38
Total	$	961,151	$	(214,927	)	$	746,224
Indefinite-lived:
Trademarks and tradenames						$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	243,679	$	(111,185	)	$	132,494
Customer lists	718,649		(78,621		)	640,028
Other	4,660		(4,597		)	63
Total	$	966,988	$	(194,403	)	$	772,585
Indefinite-lived:
Trademarks and tradenames						$	90,288

Schedule of Indefinite-Lived Intangible Assets

Intangible assets at June 29, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
June 29, 2018
Definite-lived:
Purchased technology and patents	$	242,561	$	(118,399	)	$	124,162
Customer lists	713,930		(91,906		)	622,024
Other	4,660		(4,622		)	38
Total	$	961,151	$	(214,927	)	$	746,224
Indefinite-lived:
Trademarks and tradenames						$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	243,679	$	(111,185	)	$	132,494
Customer lists	718,649		(78,621		)	640,028
Other	4,660		(4,597		)	63
Total	$	966,988	$	(194,403	)	$	772,585
Indefinite-lived:
Trademarks and tradenames						$	90,288

Schedule of Finite-Lived Intangible Assets, Amortization Expense

Aggregate intangible asset amortization expense is comprised of the following (in thousands):



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Cost of sales	$	3,673	$	3,761	$	7,389	$	7,496
Selling, general and administrative expenses	6,808		6,250		13,706		12,462
Research, development and engineering costs	38		136		77		272
Discontinued operations	350		899		1,410		1,794
Total intangible asset amortization expense	$	10,869	$	11,046	$	22,582	$	22,024

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Estimated future intangible asset amortization expense based on the carrying value as of June 29, 2018 is as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Amortization Expense	$	19,842	$	40,556	$	40,870	$	40,013	$	38,871	$	566,072

Debt (Tables)

6 Months Ended

Jun. 29, 2018

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Long-term debt is comprised of the following (in thousands):



	June 29, 2018			December 29, 2017
Senior secured term loan A	$	321,094		$	335,157
Senior secured term loan B	812,286			873,286
9.125% senior notes due 2023	360,000			360,000
Revolving line of credit	74,000			74,000
Unamortized discount on term loan B and debt issuance costs	(28,690		)	(33,278		)
Total debt	1,538,690			1,609,165
Current portion of long-term debt	(35,156		)	(30,469		)
Total long-term debt	$	1,503,534		$	1,578,696

Schedule of Maturities of Long-term Debt

Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2018 and the next four years and thereafter, excluding any discounts or premiums, as of June 29, 2018 are as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Future minimum principal payments	$	16,406	$	37,500	$	111,500	$	229,688	$	812,286	$	360,000

Schedule of Deferred Financing Fees

The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands):



December 29, 2017	$	2,808
Amortization during the period	(495		)
June 29, 2018	$	2,313

The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):



	Debt Issuance Costs			Unamortized Discount on TLB Facility			Total
December 29, 2017	$	26,889		$	6,389		$	33,278
Write-off of debt issuance costs and unamortized discount⁽¹⁾	(1,039		)	(435		)	(1,474		)
Amortization during the period	(2,544		)	(570		)	(3,114		)
June 29, 2018	$	23,306		$	5,384		$	28,690

⁽¹⁾

The Company prepaid portions of its TLB Facility during 2018 and 2017. The Company recognized losses from extinguishment of debt during the three and six months ended June 29, 2018 of $0.4 million and $1.5 million, respectively. The Company recognized losses from extinguishment of debt during the three and six months ended June 30, 2017 of $0.9 million and $2.5 million, respectively. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations.

Schedule of Interest Rate Derivatives

Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of June 29, 2018 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	Pay Fixed Rate		Receive Current Floating Rate		Fair Value		Balance Sheet Location
$	200,000	Jun-17	Jun-20	1.1325	%	2.1029	%	$	5,756	Other Long-Term Assets

Benefit Plans (Tables)

6 Months Ended

Jun. 29, 2018

Defined Benefit Plan [Abstract]

Schedule of Net Defined Benefit Cost

Net defined benefit cost attributable to employees of the AS&O Product Line located in France and Germany are reported within discontinued operations.

The following tables set forth the components of the Company’s net periodic expense relating to retirement benefit plans (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Service cost	$	122		$	115		$	249		$	225
Interest cost	45			40			91			78
Amortization of net loss	16			19			32			36
Expected return on plan assets	(5		)	(6		)	(9		)	(10		)
Net defined benefit cost	178			168			363			329
Less: Discontinued operations	109			101			223			198
Net defined benefit cost - continuing operations	$	69		$	67		$	140		$	131

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 29, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The components and classification of stock-based compensation expense were as follows (in thousands):



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Stock options	$	214	$	283	$	545	$	993
RSAs and RSUs (time-based)	1,338		1,155		3,416		3,359
Performance-based RSUs (“PSUs”)	1,333		1,843		2,146		3,598
Total stock-based compensation expense	2,885		3,281		6,107		7,950
Less: Discontinued operations	685		349		924		582
Stock-based compensation expense - continuing operations	$	2,200	$	2,932	$	5,183	$	7,368

Cost of sales	$	200	$	259	$	376	$	337
Selling, general and administrative expenses	1,968		2,493		4,747		4,493
Research, development and engineering costs	31		150		55		245
Other operating expenses	1		30		5		2,293
Discontinued operations	685		349		924		582
Total stock-based compensation expense	$	2,885	$	3,281	$	6,107	$	7,950

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The weighted average fair value and assumptions used to value options granted are as follows:



	Six Months Ended
	June 29, 2018			June 30, 2017
Weighted average fair value	$	14.89		$	10.58
Risk-free interest rate	2.21		%	1.69		%
Expected volatility	39		%	37		%
Expected life (in years)	4.0			4.1
Expected dividend yield	—		%	—		%

Schedule of Share-based Compensation, Stock Options Activity

The following table summarizes the Company’s stock option activity:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Millions)
Outstanding at December 29, 2017	931,353		$	30.89
Granted	28,447		45.13
Exercised	(108,305	)	33.47
Forfeited or expired	(17,542	)	38.77
Outstanding at June 29, 2018	833,953		$	30.87	5.4	$	28.2
Exercisable at June 29, 2018	701,729		$	29.88	4.8	$	24.4

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

The following table summarizes RSA and RSU activity:



	Time-Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	163,431		$	35.96
Granted	147,878		49.30
Vested	(11,999	)	49.78
Forfeited	(4,453	)	43.62
Nonvested at June 29, 2018	294,857		$	41.97

The following table summarizes PSU activity:



	Performance- Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	469,889		$	32.37
Granted	159,669		45.37
Vested	(127,191	)	34.29
Forfeited	(147,555	)	34.31
Nonvested at June 29, 2018	354,812		$	36.72

Other Operating Expenses, Net (Tables)

6 Months Ended

Jun. 29, 2018

Other Income and Expenses [Abstract]

Schedule of Other Operating Cost and Expense By Component

Other Operating Expenses is comprised of the following (in thousands):



	Three Months Ended					Six Months Ended
	June 29, 2018			June 30, 2017		June 29, 2018		June 30, 2017
Strategic reorganization and alignment	$	3,727		$	—	$	5,781	$	—
Manufacturing alignment to support growth	1,103			—		1,616		—
Consolidation and optimization initiatives	(14		)	2,729		561		5,076
Acquisition and integration expenses	—			2,970		—		7,790
Asset dispositions, severance and other	(124		)	1,028		518		5,555
Other operating expenses - continuing operations	4,692			6,727		8,476		18,421
Discontinued operations	2,497			193		3,990		270
Total other operating expenses	$	7,189		$	6,920	$	12,466	$	18,691

Schedule of Changes in Accrued Liabilities

The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):



	Severance and Retention			Other			Total
December 29, 2017	$	1,308		$	—		$	1,308
Restructuring charges	4,427			3,531			7,958
Cash payments	(4,514		)	(1,336		)	(5,850		)
June 29, 2018	$	1,221		$	2,195		$	3,416

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 29, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranty Liability

The change in product warranty liability was comprised of the following (in thousands):



December 29, 2017	$	2,820
Additions to warranty reserve	555
Warranty claims settled	(78		)
June 29, 2018	$	3,297

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Increase (decrease) in sales	$	(141	)	$	163		$	(2	)	$	139
Increase (decrease) in cost of sales	(159		)	(179		)	(595		)	883
Ineffective portion of change in fair value	—			—			—			—

Schedule of Foreign Exchange Contracts, Statement of Financial Position

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of June 29, 2018 is as follows (dollars in thousands):



Aggregate Notional Amount		Start Date	End Date	$/Foreign Currency		Fair Value			Balance Sheet Location
$	3,000	Jul 2018	Dec 2018	0.0500	Peso	$	(16	)	Accrued expenses
15,199		Jan 2018	Dec 2018	0.0507	Peso	(313		)	Accrued expenses
12,300		Jan 2018	Dec 2018	1.2059	Euro	(333		)	Accrued expenses

Earnings (Loss) Per Share (EPS) (Tables)

6 Months Ended

Jun. 29, 2018

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

(in thousands, except per share amounts):



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Numerator for basic and diluted EPS:
Income from continuing operations	$	23,056		$	9,559		$	36,140		$	12,507
Loss from operations of discontinued operations	(3,034		)	$	(6,569	)	(8,000		)	(13,856		)
Net income (loss)	$	20,022		$	2,990		$	28,140		$	(1,349	)

Denominator for basic and diluted EPS:
Weighted average shares outstanding - Basic	32,038			31,302			31,970			31,159
Dilutive effect of assumed exercise of stock options, restricted stock and RSUs	682			680			602			674
Weighted average shares outstanding - Diluted	32,720			31,982			32,572			31,833

Basic earnings (loss) per share:
Income from continuing operations	$	0.72		$	0.31		$	1.13		$	0.40
Loss from discontinued operations	(0.09		)	(0.21		)	(0.25		)	(0.44		)
Basic earnings (loss) per share	0.62			0.10			0.88			(0.04		)

Diluted earnings (loss) per share:
Income from continuing operations	$	0.70		$	0.30		$	1.11		$	0.39
Loss from discontinued operations	(0.09		)	(0.21		)	(0.25		)	(0.44		)
Diluted earnings (loss) per share	0.61			0.09			0.86			(0.04		)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):



	Three Months Ended		Six Months Ended
	June 29, 2018	June 30, 2017	June 29, 2018	June 30, 2017
Time-vested stock options, restricted stock and RSUs	—	556	50	1,599
Performance-vested restricted stock and PSUs	92	180	122	451

Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 29, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income is comprised of the following (in thousands):



	Defined Benefit Plan Liability			Cash Flow Hedges			Foreign Currency Translation Adjustment			Total Pre-Tax Amount			Tax			Net-of-Tax Amount
March 30, 2018	$	(1,422	)	$	7,733		$	63,641		$	69,952		$	(923	)	$	69,029
Unrealized loss on cash flow hedges	—			(2,223		)	—			(2,223		)	467			(1,756		)
Realized gain on foreign currency hedges	—			(18		)	—			(18		)	3			(15		)
Realized gain on interest rate swap hedges	—			(398		)	—			(398		)	83			(315		)
Foreign currency translation loss	—			—			(25,885		)	(25,885		)	—			(25,885		)
June 29, 2018	$	(1,422	)	$	5,094		$	37,756		$	41,428		$	(370	)	$	41,058

December 29, 2017	$	(1,422	)	$	3,418		$	50,200		$	52,196		$	(17	)	$	52,179
Unrealized gain on cash flow hedges	—			2,901			—			2,901			(609		)	2,292
Realized gain on foreign currency hedges	—			(593		)	—			(593		)	124			(469		)
Realized gain on interest rate swap hedges	—			(632		)	—			(632		)	132			(500		)
Foreign currency translation loss	—			—			(12,444		)	(12,444		)	—			(12,444		)
June 29, 2018	$	(1,422	)	$	5,094		$	37,756		$	41,428		$	(370	)	$	41,058



March 31, 2017	$	(1,475	)	$	4,112		$	(9,124	)	$	(6,487	)	$	(1,227	)	$	(7,714	)
Unrealized gain on cash flow hedges	—			1,069			—			1,069			(374		)	695
Realized gain on foreign currency hedges	—			(342		)	—			(342		)	120			(222		)
Realized gain on interest rate swap hedges	—			(238		)	—			(238		)	83			(155		)
Foreign currency translation gain	—			—			34,599			34,599			—			34,599
June 30, 2017	$	(1,475	)	$	4,601		$	25,475		$	28,601		$	(1,398	)	$	27,203

December 30, 2016	$	(1,475	)	$	1,420		$	(15,660	)	$	(15,715	)	$	(285	)	$	(16,000	)
Unrealized gain on cash flow hedges	—			2,781			—			2,781			(973		)	1,808
Realized loss on foreign currency hedges	—			744			—			744			(260		)	484
Realized gain on interest rate swap hedges	—			(344		)	—			(344		)	120			(224		)
Foreign currency translation gain	—			—			41,135			41,135			—			41,135
June 30, 2017	$	(1,475	)	$	4,601		$	25,475		$	28,601		$	(1,398	)	$	27,203

Fair Value Measurements (Tables)

6 Months Ended

Jun. 29, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):



	Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
June 29, 2018
Assets: Interest rate swap (Note 5)	$	5,756	$	—	$	5,756	$	—
Liabilities: Foreign currency contracts (Note 10)	662		—		662		—

December 29, 2017
Assets: Interest rate swaps	$	4,279	$	—	$	4,279	$	—
Liabilities: Foreign currency contracts	861		—		861		—

Segment Information (Tables)

6 Months Ended

Jun. 29, 2018

Segment Reconciliation [Abstract]

Reconciliation of Revenue from Segments to Consolidated



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Segment sales from continuing operations by product line:
Medical
Cardio & Vascular	$	148,766	$	130,718	$	285,629	$	254,202
Cardiac & Neuromodulation	115,941		106,173		224,851		209,928
Advanced Surgical, Orthopedics & Portable Medical	34,751		28,282		68,692		56,433
Total Medical	299,458		265,173		579,172		520,563
Non-Medical	15,006		15,743		27,718		27,089
Total sales from continuing operations	$	314,464	$	280,916	$	606,890	$	547,652

Reconciliation of Operating Profit (Loss) from Segments to Consolidated



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Segment income from continuing operations:
Medical	$	61,179		$	51,557		$	108,694		$	99,274
Non-Medical	4,393			4,940			7,591			6,502
Total segment income from continuing operations	65,572			56,497			116,285			105,776
Unallocated operating expenses	(21,214		)	(20,435		)	(41,884		)	(45,811		)
Operating income from continuing operations	44,358			36,062			74,401			59,965
Unallocated expenses, net	(12,563		)	(26,248		)	(24,148		)	(46,414		)
Income before taxes from continuing operations	$	31,795		$	9,814		$	50,253		$	13,551

Revenue From Contracts With Customers (Tables)

6 Months Ended

Jun. 29, 2018

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

The following table presents revenues by customer.



	Three Months Ended				Six Months Ended
	June 29, 2018				June 29, 2018
Customer	Medical		Non-Medical		Medical		Non-Medical
Customer A	21	%	—	%	21	%	—	%
Customer B	20	%	—	%	20	%	—	%
Customer C	11	%	—	%	11	%	—	%
Customer D	—	%	35	%	—	%	28	%
All other customers	48	%	65	%	48	%	72	%

The following table presents revenues by ship to country.



	Three Months Ended		Six Months Ended
	June 29, 2018		June 29, 2018
Ship to Location	Medical	Non-Medical	Medical	Non-Medical
United States	55%	69%	56%	69%
Puerto Rico	13%	—%	13%	—%
Canada	—%	—%	—%	10%
All other Countries	32%	31%	31%	21%

Impact of Recently Issued Accounting Standards (Tables)

6 Months Ended

Jun. 29, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Summary of Recently Issued Accounting Standards

The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB"):



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.	The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users.	December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.	The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.
In August 2017, the FASB issued ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities.	The new guidance improves the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results.	December 29, 2018. Early adoption is permitted.	The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.
In March 2017, the FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.	The new guidance clarifies the presentation and classification of the components of net periodic benefit costs in the consolidated statement of operations.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, the beginning of its 2018 fiscal year, using the retrospective transition method, as part of the FASB's simplification initiative. See Adoption of ASU 2017-07 section below for additional information.
In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory.	The new guidance requires the income tax consequences of an intra-entity transfer of assets other than inventory to be recognized when the transfer occurs rather than deferring until an outside sale has occurred.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments.	The new guidance clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In February 2016, the FASB issued ASU 2016-02, Leases.	The new guidance supersedes the lease guidance under ASC Topic 840, Leases, resulting in the creation of FASB ASC Topic 842, Leases. The guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.	December 29, 2018. Early adoption is permitted.	The Company is currently evaluating its population of leases, and is continuing to assess all potential impacts of the standard, but currently believes the most significant impact relates to its accounting for real estate operating leases. The Company anticipates recognition of additional assets and corresponding liabilities related to leases upon adoption, but has not yet quantified these at this time. The Company plans to adopt the standard effective December 29, 2018.

(16.) IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.	The new guidance updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. Since that date, the FASB has issued additional ASUs clarifying certain aspects of ASU 2014-09.	The new guidance requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provides alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. (See Note 15, “Revenue from Contracts with Customers”).

Basis of Presentation (Narrative) (Details)	3 Months Ended
Basis of Presentation (Narrative) (Details)	Jun. 29, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Fiscal Period Duration	91 days	91 days

Discontinued Operations (Assets and Liabilities of AS&O Business) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 28, 2018	Jun. 29, 2018	Dec. 29, 2017	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		$ 1,204		$ 5,564
Current assets of discontinued operations held for sale		439,752	$ 106,746
Noncurrent assets of discontinued operations held for sale		0	344,634
Current liabilities of discontinued operations held for sale		56,243	47,703
Deferred taxes and other long-term liabilities		0	14,966
Discontinued Operations, Held-for-sale [Member] \| AS&O Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		1,204	6,755
Accounts receivable, net of allowance for doubtful accounts of $0.2 million and $0.3 million, respectively		45,757	47,611
Inventories		52,953	50,796
Other current assets		3,325	1,584
Property, plant and equipment, net		131,007	0
Goodwill		149,733	0
Other intangible assets, net		55,773	0
Current assets of discontinued operations held for sale		439,752	106,746
Property, plant and equipment, net		0	135,195
Goodwill		0	150,368
Other intangible assets, net		0	57,520
Other noncurrent assets		0	1,551
Noncurrent assets of discontinued operations held for sale		0	344,634
Total assets		439,752	451,380
Accounts payable and other current liabilities		51,843	47,703
Deferred taxes		4,400	0
Current liabilities of discontinued operations held for sale		56,243	47,703
Deferred taxes and other long-term liabilities		0	14,966
Total liabilities		56,243	62,669
Net assets divested		383,509	388,711
Allowance for doubtful accounts		$ 300	$ 200
Scenario, Forecast [Member] \| Subsequent Event [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] \| AS&O Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 600,000

Discontinued Operations (Loss from Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from operations of discontinued operations	$ (1,374)	$ (5,698)	$ (7,623)	$ (13,630)
Provision for income taxes	1,660	871	377	226
Loss from discontinued operations	(3,034)	(6,569)	(8,000)	(13,856)
AS&O Business [Member] \| Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	88,701	81,803	178,020	160,480
Cost of sales	71,276	71,706	148,357	141,185
Gross profit	17,425	10,097	29,663	19,295
Selling, general and administrative expenses	4,096	4,578	8,905	9,283
Research, development and engineering costs	1,090	1,649	2,352	3,423
Other operating expenses	2,497	193	3,990	270
Interest expense	11,007	10,589	21,857	21,115
Other (income) loss, net	109	(1,214)	182	(1,166)
Loss from operations of discontinued operations	(1,374)	(5,698)	(7,623)	(13,630)
Provision for income taxes	1,660	871	377	226
Loss from discontinued operations	$ (3,034)	$ (6,569)	$ (8,000)	$ (13,856)

Discontinued Operations Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) - AS&O Business [Member] - Discontinued Operations, Held-for-sale [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities	$ (5,465)	$ (1,692)
Cash used in investing activities	(3,596)	(9,141)
Depreciation and amortization	7,450	10,507
Capital expenditures	$ 3,610	$ 9,214

Inventories (Details) - USD ($) $ in Thousands	Jun. 29, 2018	Dec. 29, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 85,767	$ 85,050
Work-in-process	76,761	63,620
Finished goods	32,449	28,068
Total	$ 194,977	$ 176,738

Goodwill and Other Intangible Assets, Net (Schedule of Indefinite-Lived Intangible Assets and Goodwill) (Details) $ in Thousands	6 Months Ended
	Jun. 29, 2018 USD ($)
Goodwill [Roll Forward]
Goodwill	$ 839,870
Foreign currency translation	(4,312)
Goodwill	835,558
Medical Segment [Member]
Goodwill [Roll Forward]
Goodwill	822,870
Foreign currency translation	(4,312)
Goodwill	818,558
Non-Medical Segment [Member]
Goodwill [Roll Forward]
Goodwill	17,000
Foreign currency translation	0
Goodwill	$ 17,000

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Jun. 29, 2018	Dec. 29, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 961,151	$ 966,988
Accumulated Amortization	(214,927)	(194,403)
Total estimated amortization expense	746,224	772,585
Trademarks And Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	90,288	90,288
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	242,561	243,679
Accumulated Amortization	(118,399)	(111,185)
Total estimated amortization expense	124,162	132,494
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	713,930	718,649
Accumulated Amortization	(91,906)	(78,621)
Total estimated amortization expense	622,024	640,028
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,660	4,660
Accumulated Amortization	(4,622)	(4,597)
Total estimated amortization expense	$ 38	$ 63

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 10,869	$ 11,046	$ 22,582	$ 22,024
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	3,673	3,761	7,389	7,496
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	6,808	6,250	13,706	12,462
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 38	$ 136	$ 77	$ 272

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) $ in Thousands	Jun. 29, 2018 USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2018	$ 19,842
2019	40,556
2020	40,870
2021	40,013
2022	38,871
After 2022	$ 566,072

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jun. 29, 2018	Dec. 29, 2017	Oct. 27, 2015
Debt Instrument [Line Items]
Unamortized discount on term loan B and debt issuance costs	$ (28,690)	$ (33,278)
Total debt	1,538,690	1,609,165
Current portion of long-term debt	(35,156)	(30,469)
Total long-term debt	$ 1,503,534	1,578,696
Senior Notes [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Stated interest rate	9.125%		9.125%
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 321,094	335,157
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	812,286	873,286
Secured Debt [Member] \| Loans Payable [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	360,000	360,000
Secured Debt [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 74,000	$ 74,000

Debt (Credit Facility) (Details)		6 Months Ended
Debt (Credit Facility) (Details)	Oct. 27, 2015 USD ($) loan_facility	Jun. 29, 2018 USD ($)
Senior Notes [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 360,000,000
Debt Instrument, Maturity Date	Nov. 01, 2023
Long-term Debt, Fair Value		$ 392,000,000
Stated interest rate	9.125%	9.125%
Secured Debt [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 200,000,000
Debt Instrument, Maturity Date	Oct. 27, 2020
Revolving line of credit		$ 74,000,000
Line of Credit Facility, Remaining Borrowing Capacity		116,800,000
Letters of Credit Outstanding, Amount		$ 9,200,000
Debt Weighted Average Interest Rate		5.34%
Secured Debt [Member] \| Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, Number Of Additional Term Loan Facilities That May Be Added \| loan_facility	1
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 375,000,000
Debt Instrument, Maturity Date	Oct. 27, 2021
Debt Weighted Average Interest Rate		5.36%
Debt Instrument, Covenant Compliance, Maximum Leverage Ratio	6.0
Debt Instrument, Covenant Compliance, Adjusted EBITDA To Interest Expense Ratio	2.75
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,025,000,000
Debt Instrument, Discount, Percentage	1.00%
Reduction to the variable rate basis spread		0.25%
Debt Instrument, Maturity Date	Oct. 27, 2022
Debt Weighted Average Interest Rate		5.30%
Long-term Debt, Fair Value		$ 815,000,000
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%
Debt Instrument, Interest Rate, Floor	1.00%
Secured Debt [Member] \| Swingline Loans [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 15,000,000
Secured Debt [Member] \| Standby Letters of Credit [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 25,000,000
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.175%
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	0.75%
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	1.75%
Secured Debt [Member] \| Minimum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	0.75%
Secured Debt [Member] \| Minimum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	1.75%
Secured Debt [Member] \| Maximum [Member] \| Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Jun. 29, 2018 USD ($)
Debt Disclosure [Abstract]
2018	$ 16,406
2019	37,500
2020	111,500
2021	229,688
2022	812,286
After 2022	$ 360,000

Debt (Schedule of Deferred Financing Fees) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Deferred Finance Costs [Roll Forward]
Total, Beginning Balance			$ 33,278
Amortization during the period			(5,083)	$ (6,241)
Total, Ending Balance	$ 28,690		28,690
Loss on extinguishment of debt	400	$ 900	1,500	$ 2,500
Revolving Credit Facility [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance			2,808
Amortization during the period			(495)
Deferred Finance Costs, Net, Ending Balance	2,313		2,313
Term Loan And Senior Notes [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance			26,889
Write-off of debt issuance costs and unamortized discount			(1,039)
Amortization during the period			(2,544)
Deferred Finance Costs, Net, Ending Balance	23,306		23,306
Total, Beginning Balance			33,278
Write-off of debt issuance costs and unamortized discount			(1,474)
Amortization during the period			(3,114)
Total, Ending Balance	28,690		28,690
Term Loan B (TLB) Facility [Member]
Deferred Finance Costs [Roll Forward]
Unamortized Discount on TLB Facility, Beginning Balance			6,389
Write-off of debt issuance costs and unamortized discount			(435)
Amortization during the period			(570)
Unamortized Discount on TLB Facility, Ending Balance	$ 5,384		$ 5,384

Debt (Schedule of Interest Rate Swaps and Details) (Details) - USD ($)	1 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 29, 2018	Jun. 30, 2017
Interest Rate Swap 3 [Member]
Derivative [Line Items]
Derivative, Term of Contract	3 years
Derivative Liability, Notional Amount	$ 200,000,000
Notional Amount		$ 200,000,000
Pay Fixed Rate		1.1325%
Receive Current Floating Rate		2.1029%
Fair Value, Asset		$ 5,756,000
Interest Rate Swap [Member]
Derivative [Line Items]
Gain (Loss) Recognized In Income Ineffective Portion		0	$ 0
Reduction (Increase) to Interest Expense		600,000	$ (300,000)
Gain expected to be reclassified into earnings within the next twelve months		$ 2,500,000

Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 122	$ 115	$ 249	$ 225
Interest cost	45	40	91	78
Amortization of net loss	16	19	32	36
Expected return on plan assets	(5)	(6)	(9)	(10)
Net defined benefit cost	178	168	363	329
Discontinued Operations [Member]
Defined Benefit Plan Disclosure [Line Items]
Net defined benefit cost	109	101	223	198
Continuing Operations [Member]
Defined Benefit Plan Disclosure [Line Items]
Net defined benefit cost	$ 69	$ 67	$ 140	$ 131

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 2,885	$ 3,281	$ 6,107	$ 7,950
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	200	259	376	337
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,968	2,493	4,747	4,493
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	31	150	55	245
Other Operating Income (Expense) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1	30	5	2,293
Income Statement Location, Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	685	349	924	582
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	214	283	545	993
RSAs and RSUs (time-based) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,338	1,155	3,416	3,359
Performance-based RSUs (PSUs) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,333	1,843	2,146	3,598
Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	685	349	924	582
Continuing Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 2,200	$ 2,932	$ 5,183	$ 7,368

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value	$ 14.89	$ 10.58
Risk-free interest rate	2.21%	1.69%
Expected volatility	39.00%	37.00%
Expected life (in years)	4 years	4 years 1 month 6 days
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 29, 2018 USD ($) $ / shares shares
Stock Option Activity (in shares)
Options Outstanding, Beginning \| shares	931,353
Granted \| shares	28,447
Exercised \| shares	(108,305)
Forfeited or expired \| shares	(17,542)
Options Outstanding, Ending \| shares	833,953
Options Exercisable \| shares	701,729
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning \| $ / shares	$ 30.89
Granted \| $ / shares	45.13
Exercised \| $ / shares	33.47
Forfeited or expired \| $ / shares	38.77
Options Outstanding, Ending \| $ / shares	30.87
Options Exercisable \| $ / shares	$ 29.88
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	5 years 5 months
Options Exercisable, Weighted Average Remaining Contractual Term	4 years 10 months
Options Outstanding, Intrinsic Value \| $	$ 28.2
Options Exercisable, Intrinsic Value \| $	$ 24.4

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	6 Months Ended
	Jun. 29, 2018 $ / shares shares
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning \| shares	163,431
Granted \| shares	147,878
Vested \| shares	(11,999)
Forfeited \| shares	(4,453)
Nonvested, Ending \| shares	294,857
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning \| $ / shares	$ 35.96
Granted \| $ / shares	49.30
Vested \| $ / shares	49.78
Forfeited \| $ / shares	43.62
Nonvested, Ending \| $ / shares	$ 41.97
Performance-based RSUs (PSUs) [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning \| shares	469,889
Granted \| shares	159,669
Vested \| shares	(127,191)
Forfeited \| shares	(147,555)
Nonvested, Ending \| shares	354,812
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning \| $ / shares	$ 32.37
Granted \| $ / shares	45.37
Vested \| $ / shares	34.29
Forfeited \| $ / shares	34.31
Nonvested, Ending \| $ / shares	$ 36.72

Stock-Based Compensation (Additional Information) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acceleration of remaining compensation expense	$ 2.2
Performance period		3 years
Expected life (in years)		4 years	4 years 1 month 6 days
Risk-free interest rate		2.21%	1.69%
Expected dividend yield		0.00%	0.00%
Expected volatility		39.00%	37.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted		0.3
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted		0.2
Performance Shares [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Shares [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Financial Performance Stock Units [Member] \| Performance Period Ending January 1, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted		0.1
TSR Performance Stock Units [Member] \| Performance Period Ending January 1, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted		0.1
Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance-based RSUs (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)		2 years 11 months
Risk-free interest rate		2.28%
Expected dividend yield		0.00%
Expected volatility		40.00%

Other Operating Expenses, Net (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	$ 4,692	$ 6,727	$ 8,476	$ 18,421
Discontinued operations	2,497	193	3,990	270
Total other operating expenses	7,189	6,920	12,466	18,691
Strategic Reorganization And Alignment [Member]
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	3,727	0	5,781	0
Manufacturing Alignment To Support Growth [Member]
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	1,103	0	1,616	0
Consolidation And Optimization Initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	(14)	2,729	561	5,076
Acquisition and Integration Expenses [Member]
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	0	2,970	0	7,790
Asset Dispositions, Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Other operating expenses - continuing operations	$ (124)	$ 1,028	$ 518	$ 5,555

Other Operating Expenses, Net (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 29, 2017	Jun. 29, 2018
Strategic Reorganization And Alignment [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception			$ 15.5
Strategic Reorganization And Alignment [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		$ 28.0
Expected cash outlays		16.0
Strategic Reorganization And Alignment [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		30.0
Expected cash outlays		20.0
Manufacturing Alignment To Support Growth [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception			$ 2.0
Manufacturing Alignment To Support Growth [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		9.0
Expected capital expenditures		4.0
Manufacturing Alignment To Support Growth [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		11.0
Expected capital expenditures		6.0
Acquisition And Integration Costs [Member] \| Lake Region Medical [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition related transaction costs	$ 3.0
Acquisition and integration costs accrued		0.4
Asset Dispositions, Severance And Other [Member]
Restructuring Cost and Reserve [Line Items]
Leadership transition costs		$ 5.3

Other Operating Expenses, Net (Schedule of Restructuring Reserve By Type of Cost) (Details) - Consolidation And Optimization Initiatives [Member] $ in Thousands	6 Months Ended
	Jun. 29, 2018 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 1,308
Restructuring charges	7,958
Cash payments	(5,850)
Restructuring Reserve, Ending Balance	3,416
Severance And Retention [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,308
Restructuring charges	4,427
Cash payments	(4,514)
Restructuring Reserve, Ending Balance	1,221
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	3,531
Cash payments	(1,336)
Restructuring Reserve, Ending Balance	$ 2,195

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017	Dec. 29, 2017
Income Tax Disclosure [Abstract]
Unrecognized foreign earnings and profits					$ 147,500
Provisional income tax expense					14,700
Tax benefit from revaluation of net deferred tax liabilities					$ 56,500
Effective income tax rate	27.50%	2.60%
Income (loss) before provision for income taxes	$ 31,795	$ 9,814	$ 50,253	$ 13,551
Federal statutory tax rate			21.00%		35.00%
Unrecognized Tax Benefits	6,500		$ 6,500
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	1,100		1,100
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 6,200		$ 6,200

Commitments and Contingencies (Narrative) (Details)		6 Months Ended
Commitments and Contingencies (Narrative) (Details)	Jan. 26, 2016 USD ($) patent	Jun. 29, 2018 USD ($)
Gain Contingencies [Line Items]
Gain (Loss) Related to Litigation Settlement		$ 0
Product Warranty Description		The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Positive Outcome of Litigation [Member]
Gain Contingencies [Line Items]
Gain Contingency, Patents Found Infringed upon, Number \| patent	2
Amount awarded from other party	$ 37,500,000

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	6 Months Ended
	Jun. 29, 2018 USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
December 29, 2017	$ 2,820
Additions to warranty reserve	555
Warranty claims settled	(78)
June 29, 2018	$ 3,297

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 29, 2018 USD ($)	Jun. 30, 2017 USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Increase (decrease) in sales	$ (141)	$ 163	$ (2)	$ 139
Increase (decrease) in cost of sales	(159)	(179)	(595)	883
Ineffective portion of change in fair value	0	$ 0	0	$ 0
Foreign Currency Cash Flow Hedge [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	700		700
FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	3,000		$ 3,000
Start Date			Jul. 02, 2018
End Date			Dec. 28, 2018
FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	15,199		$ 15,199
Start Date			Jan. 01, 2018
End Date			Dec. 28, 2018
FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	12,300		$ 12,300
Start Date			Jan. 01, 2018
End Date			Dec. 28, 2018
Accrued Expenses [Member] \| FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	(16)		$ (16)
Accrued Expenses [Member] \| FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	(313)		(313)
Accrued Expenses [Member] \| FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	$ (333)		$ (333)
Peso [Member] \| FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	0.0500		0.0500
Peso [Member] \| FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	0.0507		0.0507
Euro [Member] \| FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	1.2059		1.2059

Earnings (Loss) Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Income from continuing operations	$ 23,056	$ 9,559	$ 36,140	$ 12,507
Loss from operations of discontinued operations	(3,034)	(6,569)	(8,000)	(13,856)
Net income (loss)	$ 20,022	$ 2,990	$ 28,140	$ (1,349)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic (in shares)	32,038,000	31,302,000	31,970,000	31,159,000
Stock options, restricted stock and restricted stock units (in shares)	682,000	680,000	602,000	674,000
Denominator for diluted EPS (in shares)	32,720,000	31,982,000	32,572,000	31,833,000
Basic earnings (loss) per share:
Income from continuing operations (in dollars per share)	$ 0.72	$ 0.31	$ 1.13	$ 0.40
Loss from discontinued operations (in dollars per share)	(0.09)	(0.21)	(0.25)	(0.44)
Basic (in dollars per share)	0.62	0.10	0.88	(0.04)
Diluted earnings (loss) per share:
Income from continuing operations (in dollars per share)	0.70	0.30	1.11	0.39
Loss from discontinued operations (in dollars per share)	(0.09)	(0.21)	(0.25)	(0.44)
Diluted (in dollars per share)	$ 0.61	$ 0.09	$ 0.86	$ (0.04)
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units (in shares)	0	556,000	50,000	1,599,000
Performance-vested stock options and restricted stock units (in shares)	92,000	180,000	122,000	451,000

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,422)	$ (1,475)	$ (1,422)	$ (1,475)
Defined Benefit Plan Liability, Ending	(1,422)	(1,475)	(1,422)	(1,475)
Cash Flow Hedges
Cash Flow Hedges, Beginning	7,733	4,112	3,418	1,420
Unrealized loss on cash flow hedges	2,223	(1,069)	(2,901)	(2,781)
Realized gain loss on foreign currency hedges - before tax	(18)	(342)	(593)	744
Realized gain loss on interest rate swaps - before tax	(398)	(238)	(632)	(344)
Cash Flow Hedges, End	5,094	4,601	5,094	4,601
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	63,641	(9,124)	50,200	(15,660)
Net foreign currency translation gain (loss)	(25,885)	34,599	(12,444)	41,135
Foreign Currency Translation Adjustment, End	37,756	25,475	37,756	25,475
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	69,952	(6,487)	52,196	(15,715)
Unrealized loss on cash flow hedges	2,223	(1,069)	(2,901)	(2,781)
Realized gain loss on foreign currency hedges - before tax	(18)	(342)	(593)	744
Realized gain loss on interest rate swaps - before tax	(398)	(238)	(632)	(344)
Net foreign currency translation gain (loss)	(25,885)	34,599	(12,444)	41,135
Total Pre-Tax Amount, End	41,428	28,601	41,428	28,601
Tax
Tax, Beginning	(923)	(1,227)	(17)	(285)
Unrealized gain (loss) on cash flow hedges	467	(374)	(609)	(973)
Realized gain loss on foreign currency contracts - tax	3	120	124	(260)
Realized gain loss on interest rate swap hedges - tax	83	83	132	120
Net foreign currency translation gain (loss)	0	0	0	0
Tax, End	(370)	(1,398)	(370)	(1,398)
Net-of-Tax Amount
Total Net-of-Tax Amount, Beginning	69,029	(7,714)	52,179	(16,000)
Unrealized gain (loss) on cash flow hedges, net of tax	1,756	(695)	(2,292)	(1,808)
Realized gain loss on foreign currency hedges, net of tax	(15)	(222)	(469)	484
Realized gain loss on interest rate swap hedges, net of tax	(315)	(155)	(500)	(224)
Foreign currency translation gain (loss)	(25,885)	34,599	(12,444)	41,135
Total Net-of-Tax Amount, End	$ 41,058	$ 27,203	$ 41,058	$ 27,203

Fair Value Measurements (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 29, 2018	Dec. 29, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	$ 662	$ 861
Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	5,756	4,279
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	0	0
Fair Value, Inputs, Level 1 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	662	861
Fair Value, Inputs, Level 2 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	5,756	4,279
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	0	0
Fair Value, Inputs, Level 3 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	$ 0	$ 0

Fair Value Measurements (Narrative) (Details) - USD ($)	6 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Jun. 29, 2018	Jun. 30, 2017	Dec. 29, 2017
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cost method and equity method investments, carrying value	$ 22,400,000		$ 20,800,000
Cost method investment	7,700,000		7,000,000
Impairment on cost method investments	0	$ 0
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Gain (loss) on equity method investments	5,000,000	$ (200,000)
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity method investment	$ 14,700,000		$ 13,800,000
Equity method investment ownership (percent)	6.60%

Segment Information (Narrative) (Details)	6 Months Ended
Segment Information (Narrative) (Details)	Jun. 29, 2018 Segment
Segment Reporting [Abstract]
Number of Reportable Segments	2

Segment Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	$ 314,464	$ 280,916	$ 606,890	$ 547,652
Operating Segments [Member] \| Medical Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	299,458	265,173	579,172	520,563
Operating Segments [Member] \| Medical Segment [Member] \| Cardio And Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	148,766	130,718	285,629	254,202
Operating Segments [Member] \| Medical Segment [Member] \| Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	115,941	106,173	224,851	209,928
Operating Segments [Member] \| Medical Segment [Member] \| Advanced Surgical, Orthopedics, and Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	34,751	28,282	68,692	56,433
Operating Segments [Member] \| Non-Medical Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	$ 15,006	$ 15,743	$ 27,718	$ 27,089

Segment Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Segment Reporting Information [Line Items]
Operating income from continuing operations	$ 44,358	$ 36,062	$ 74,401	$ 59,965
Unallocated expenses, net	(12,563)	(26,248)	(24,148)	(46,414)
Income from continuing operations before taxes	31,795	9,814	50,253	13,551
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income from continuing operations	65,572	56,497	116,285	105,776
Operating Segments [Member] \| Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income from continuing operations	61,179	51,557	108,694	99,274
Operating Segments [Member] \| Non-Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income from continuing operations	4,393	4,940	7,591	6,502
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income from continuing operations	$ (21,214)	$ (20,435)	$ (41,884)	$ (45,811)

Revenue From Contracts With Customers (Disaggregated Revenue) (Details) - Revenue from Contract with Customer [Member]	3 Months Ended	6 Months Ended
	Jun. 29, 2018	Jun. 29, 2018
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	21.00%	21.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	20.00%	20.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%	11.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	48.00%	48.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	55.00%	56.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13.00%	13.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	32.00%	31.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	35.00%	28.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	65.00%	72.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	69.00%	69.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	0.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%	10.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	31.00%	21.00%

Revenue From Contracts With Customers Revenue From Contracts With Customers (Narrative) (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 29, 2018	Jun. 29, 2018	Dec. 29, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liabilities	$ 3,200,000	$ 3,200,000	$ 2,200,000
Revenue recognized that was included in contract liability balance at beginning of period	900,000	1,300,000
Contract assets	$ 0	$ 0	$ 0
Minimum [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms		30 days
Maximum [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms		90 days

Subsequent Event (Narrative) (Details) - Subsequent Event [Member] - USD ($) $ in Millions			3 Months Ended
	Jul. 10, 2018	Jul. 02, 2018	Sep. 28, 2018
Subsequent Event [Line Items]
Long Term Supply Agreement, Term		3 years
Senior Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Payment for Debt Extinguishment or Debt Prepayment Cost	$ 31.3
Senior Notes [Member] \| Senior Secured Credit Facilities [Member]
Subsequent Event [Line Items]
Repayments of Debt	188.0
Secured Debt [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Subsequent Event [Line Items]
Repayments of Debt	74.0
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member]
Subsequent Event [Line Items]
Repayments of Debt	$ 114.0
Scenario, Forecast [Member] \| AS&O Business [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses			$ 600.0